Candida auris is a new species of Candida that is currently causing outbreaks in healthcare settings worldwide. The first outbreak in Europe was described in England in 2015, but there were already cases in Spain. C. auris is difficult to identify with classical methods and can be misidentified with different species (Rhodotorula glutinis, Saccharomyces cerevisiae, Candida haemulonii, Candida sake, or other species of Candida non-albicans), depending on the identification method used. Correct identification can be done by sequencing the ITS or D1-D2 regions or with MALDI-TOF (the species has been included in the last update of Bruker´s library).
C. auris is resistant to fluconazole, and strains resistant to amphotericin B and echinocandins have also been described. From the experience acquired so far, it is known that it is important to detect it as soon as possible to take control measures, due to its high transmission capacity and resistance pattern. Due to the difficulty of the correct identification of C. auris, if proper identification methods are not available, we recommend the referral of suspected invasive isolates to a reference mycology laboratory.
• Risk Assessment of the European Center for Disease Control (ECDC, direct link)
• Guidance for the laboratory investigation, management and infection prevention and control from cases of Candida auris elaborated by Public Health England (PHE, direct link)
• CDC Candida auris website with links to Interim Recommendations, as well as links to papers on a global WGS analysis and investigation of the first seven US cases
Researchers will present new data on this new pathogen at ECCMID 2017. Check the scientific programme, which will be published on the congress website in the course of February.